Advances in vaccination against Helicobacter pylori

References

• Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet1, 1311–1315 (1984).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Konradt M, Groll C et al. The spatial orientation of Helicobacter pylori in the gastric mucus. Proc. Natl Acad. Sci. USA101, 5024–5029 (2004).
   PubMed Web of Science ®Google Scholar
• Hazell SL, Lee A, Brady L, Hennessy W. Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J. Infect. Dis.153, 658–663 (1986).
   PubMed Web of Science ®Google Scholar
• Semino-Mora C, Doi SQ, Marty A, Simko V, Carlstedt I, Dubois A. Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma. J. Infect. Dis.187, 1165–1177 (2003).
   PubMedGoogle Scholar
• Eaton KA, Suerbaum S, Josenhans C, Krakowka S. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes. Infect. Immun.64, 2445–2448 (1996).
   PubMed Web of Science ®Google Scholar
• Guruge JL, Falk PG, Lorenz RG et al. Epithelial attachment alters the outcome of Helicobacter pylori infection. Proc. Natl Acad. Sci. USA95, 3925–3930 (1998).
   PubMed Web of Science ®Google Scholar
• Graham DY, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race and socio–economic status. Gastroenterology100, 1495–1501 (1991).
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr, Clemens J. Helicobacter in the developing world. Microbes Infect.5, 705–713 (2003).
   PubMed Web of Science ®Google Scholar
• Schwarz S, Morelli G, Kusecek B et al. Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog.4, e1000180 (2008).
   PubMed Web of Science ®Google Scholar
• Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst. Rev.CD003840 (2004).
   Google Scholar
• Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet372, 392–397 (2008).
   PubMed Web of Science ®Google Scholar
• Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology128, 1579–1605 (2005).
   PubMed Web of Science ®Google Scholar
• Nervi G, Liatopoulou S, Cavallaro LG et al. Does Helicobacter pylori infection eradication modify peptic ulcer prevalence? A 10 years’ endoscopical survey. World J. Gastroenterol.12, 2398–2401 (2006).
   PubMedGoogle Scholar
• Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract. Res. Clin. Gastroenterol.21, 315–324 (2007).
   PubMed Web of Science ®Google Scholar
• Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut53, 1374–1384 (2004).
   PubMed Web of Science ®Google Scholar
• Rupnow MF, Shachter RD, Owens DK, Parsonnet J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine20, 879–885 (2001).
   PubMedGoogle Scholar
• Windle HJ, Kelleher D, Crabtree JE. Childhood Helicobacter pylori infection and growth impairment in developing countries: a vicious cycle? Pediatrics119, e754–e759 (2007).
   PubMedGoogle Scholar
• Shahinian ML, Passaro DJ, Swerdlow DL, Mintz ED, Rodriguez M, Parsonnel J. Helicobacter pylori and epidemic Vibrio cholerae O1 infection in Peru. Lancet355, 377–378 (2000).
   PubMedGoogle Scholar
• Bhan MK, Bahl R, Sazawal S et al. Association between Helicobacter pylori infection and increased risk of typhoid fever. J. Infect. Dis.186, 1857–1860 (2002).
   PubMedGoogle Scholar
• de Vries R, Klok RM, Brouwers JR, Postma MJ. Cost–effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health. Vaccine27, 846–852 (2009).
   PubMedGoogle Scholar
• Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost–effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J. Infect. Dis.200, 1311–1317 (2009).
   PubMed Web of Science ®Google Scholar
• Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol.20, 1161–1181 (1996).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kato K, Ohara S et al. Localization of antigen-presenting cells in Helicobacter pylori-infected gastric mucosa. Pathol. Int.52, 265–271 (2002).
   PubMedGoogle Scholar
• Terres AM, Pajares JM. An increased number of follicles containing activated CD69+ helper T cells and proliferating CD71+ B cells are found in H. pylori-infected gastric mucosa. Am. J. Gastroenterol.93, 579–583 (1998).
   PubMedGoogle Scholar
• Di Tommaso A, Xiang Z, Bugnoli M et al.Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies. Infect. Immun.63, 1102–1106 (1995).
   PubMedGoogle Scholar
• Lindholm C, Quiding-Jarbrink M, Lonroth H, Hamlet A, Svennerholm AM. Local cytokine response in Helicobacter pylori-infected subjects. Infect. Immun.66, 5964–5971 (1998).
   PubMed Web of Science ®Google Scholar
• D’Elios MM, Manghetti M, De Carli M et al. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J. Immunol.158, 962–967 (1997).
   PubMed Web of Science ®Google Scholar
• Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ. Campylobacter pylori antibodies in humans. Ann. Intern. Med.109, 11–17 (1988).
   PubMed Web of Science ®Google Scholar
• Mattsson A, Quiding-Jarbrink M, Lonroth H, Hamlet A, Ahlstedt I, Svennerholm A. Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Infect. Immun.66, 2705–2712 (1998).
   PubMed Web of Science ®Google Scholar
• Hayashi S, Sugiyama T, Yokota K et al. Analysis of immunoglobulin A antibodies to Helicobacter pylori in serum and gastric juice in relation to mucosal inflammation. Clin. Diagn. Lab. Immunol.5, 617–621 (1998).
   PubMedGoogle Scholar
• Graham DY, Opekun AR, Osato MS et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut53, 1235–1243 (2004).
   PubMed Web of Science ®Google Scholar
• Nurgalieva ZZ, Conner ME, Opekun AR et al. B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infect. Immun.73, 2999–3006 (2005).
   PubMedGoogle Scholar
• Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM Jr. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J. Infect. Dis.189, 1914–1920 (2004).
   PubMed Web of Science ®Google Scholar
• Suda Y, Kim YM, Ogawa T et al. Chemical structure and biological activity of a lipid A component from Helicobacter pylori strain 206. J. Endotoxin. Res.7, 95–104 (2001).
   PubMedGoogle Scholar
• Boncristiano M, Paccani SR, Barone S et al. The Helicobacter pylori vacuolating toxin inhibits T-cell activation by two independent mechanisms. J. Exp. Med.198, 1887–1897 (2003).
   PubMed Web of Science ®Google Scholar
• Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T-lymphocyte activation. Science301, 1099–1102 (2003).
   PubMed Web of Science ®Google Scholar
• Zabaleta J, McGee DJ, Zea AH et al. Helicobacter pylori arginase inhibits T cell proliferation and reduces the expression of the TCR ζ-chain (CD3 ζ). J. Immunol.173, 586–593 (2004).
   PubMedGoogle Scholar
• Akhiani AA, Schon K, Franzen LE, Pappo J, Lycke N. Helicobacter pylori specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J. Immunol.172, 5024–5033 (2004).
   PubMedGoogle Scholar
• Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM, Lundin BS. Helicobacter pylori specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect. Immun.71, 1755–1762 (2003).
   PubMed Web of Science ®Google Scholar
• Raghavan S, Fredriksson M, Svennerholm AM, Holmgren J, Suri-Payer E. Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin. Exp. Immunol.132, 393–400 (2003).
   PubMed Web of Science ®Google Scholar
• Harris PR, Wright SW, Serrano C et al.Helicobacter pylori gastritis in children is associated with a regulatory T-cell response. Gastroenterology134, 491–499 (2008).
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Blank RB, Suffia I. Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol. Rev.212, 287–300 (2006).
   PubMed Web of Science ®Google Scholar
• Rad R, Brenner L, Bauer S et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology131, 525–537 (2006).
   PubMed Web of Science ®Google Scholar
• Lee A, Fox JG, Otto G, Murphy J. A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology99, 1315–1323 (1990).
   PubMed Web of Science ®Google Scholar
• Marchetti M, Arico B, Burroni D, Figura N, Rappuoli R, Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science267, 1655–1658 (1995).
   PubMed Web of Science ®Google Scholar
• Lee A, O’Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology112, 1386–1397 (1997).
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu. Rev. Immunol.19, 523–563 (2001).
   PubMed Web of Science ®Google Scholar
• Dubois A, Fiala N, Heman-Ackah LM et al. Natural gastric infection with Helicobacter pylori in monkeys: a model for spiral bacteria infection in humans. Gastroenterology106, 1405–1417 (1994).
   PubMed Web of Science ®Google Scholar
• Czinn SJ, Cai A, Nedrud JG. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine11, 637–642 (1993).
   PubMed Web of Science ®Google Scholar
• Doidge C, Crust I, Lee A, Buck F, Hazell S, Manne U. Therapeutic immunisation against Helicobacter infection. Lancet343, 914–915 (1994).
   PubMed Web of Science ®Google Scholar
• Corthesy-Theulaz I, Porta N, Glauser M et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology109, 115–121 (1995).
   PubMed Web of Science ®Google Scholar
• Ikewaki J, Nishizono A, Goto T, Fujioka T, Mifune K. Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection. Microbiol. Immunol.44, 29–39 (2000).
   PubMedGoogle Scholar
• McAtee CP, Lim MY, Fung K et al. Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by two-dimensional gel electrophoresis, sequence analysis, and serum profiling. Clin. Diagn. Lab. Immunol.5, 537–542 (1998).
   PubMedGoogle Scholar
• Ferrero RL, Labigne A. Cloning, expression and sequencing of Helicobacter felis urease genes. Mol. Microbiol.9, 323–333 (1993).
   PubMed Web of Science ®Google Scholar
• Ghiara P, Marchetti M, Blaser MJ et al. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect. Immun.63, 4154–4160 (1995).
   PubMed Web of Science ®Google Scholar
• Satin B, Del Giudice G, Della Bianca V et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J. Exp. Med.191, 1467–1476 (2000).
   PubMed Web of Science ®Google Scholar
• Xiang Z, Censini S, Bayeli PF et al. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect. Immun.63, 94–98 (1995).
   PubMed Web of Science ®Google Scholar
• Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc. Natl Acad. Sci. USA92, 6499–6503 (1995).
   PubMed Web of Science ®Google Scholar
• Radcliff FJ, Hazell SL, Kolesnikow T, Doidge C, Lee A. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect. Immun.65, 4668–4674 (1997).
   PubMed Web of Science ®Google Scholar
• Keenan J, Oliaro J, Domigan N et al. Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate. Infect. Immun.68, 3337–3343 (2000).
   PubMed Web of Science ®Google Scholar
• Dunkley ML, Harris SJ, McCoy RJ et al. Protection against Helicobacter pylori infection by intestinal immunisation with a 50/52-kDa subunit protein. FEMS Immunol. Med. Microbiol.24, 221–225 (1999).
   PubMedGoogle Scholar
• Kim BO, Shin SS, Yoo YH, Pyo S. Peroral immunization with Helicobacter pylori adhesin protein genetically linked to cholera toxin A2B subunits. Clin. Sci. (Lond.)100, 291–298 (2001).
   PubMed Web of Science ®Google Scholar
• Kang QZ, Duan GC, Fan QT, Xi YL. Fusion expression of Helicobacter pylori neutrophil-activating protein in E. coli. World J. Gastroenterol.11, 454–456 (2005).
   PubMedGoogle Scholar
• Wu C, Shi Y, Guo H et al. Protection against Helicobacter pylori infection in mongolian gerbil by intragastric or intramuscular administration of H. pylori multicomponent vaccine. Helicobacter13, 191–199 (2008).
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun.69, 3581–3590 (2001).
   PubMed Web of Science ®Google Scholar
• Losonsky GA, Kotloff KL, Walker RI. B-cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H. pylori seronegative individuals. Vaccine21, 562–565 (2003).
   PubMedGoogle Scholar
• Kreiss C, Buclin T, Cosma M, Corthesy-Theulaz I, Michetti P. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet347, 1630–1631 (1996).
   PubMed Web of Science ®Google Scholar
• Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology116, 804–812 (1999).
   PubMed Web of Science ®Google Scholar
• Banerjee S, Medina-Fatimi A, Nichols R et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut51, 634–640 (2002).
   PubMed Web of Science ®Google Scholar
• Sougioultzis S, Lee CK, Alsahli M et al. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine21, 194–201 (2002).
   PubMed Web of Science ®Google Scholar
• Ghiara P, Rossi M, Marchetti M et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immun.65, 4996–5002 (1997).
   PubMed Web of Science ®Google Scholar
• Rossi G, Ruggiero P, Peppoloni S et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect. Immun.72, 3252–3259 (2004).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Schultze V, Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a Phase I study. Gastroenterology135, 787–795 (2008).
   PubMed Web of Science ®Google Scholar
• DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine18, 449–459 (1999).
   PubMed Web of Science ®Google Scholar
• Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun.68, 2135–2141 (2000).
   PubMed Web of Science ®Google Scholar
• Bumann D, Metzger WG, Mansouri E et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine20, 845–852 (2001).
   PubMed Web of Science ®Google Scholar
• Metzger WG, Mansouri E, Kronawitter M et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine22, 2273–2277 (2004).
   PubMed Web of Science ®Google Scholar
• Aebischer T, Bumann D, Epple HJ et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut57, 1065–1072 (2008).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine25, 5467–5484 (2007).
   PubMed Web of Science ®Google Scholar
• Ermak TH, Giannasca PJ, Nichols R et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J. Exp. Med.188, 2277–2288 (1998).
   PubMed Web of Science ®Google Scholar
• Lee CK, Weltzin R, Thomas WD Jr et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect. Dis.172, 161–172 (1995).
   PubMed Web of Science ®Google Scholar
• Pappo J, Thomas WD Jr, Kabok Z, Taylor NS, Murphy JC, Fox JG. Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis. Infect. Immun.63, 1246–1252 (1995).
   PubMedGoogle Scholar
• Aebischer T, Laforsch S, Hurwitz R, Brombacher F, Meyer TF. Immunity against Helicobacter pylori: significance of interleukin-4 receptor alpha chain status and gender of infected mice. Infect. Immun.69, 556–558 (2001).
   PubMedGoogle Scholar
• Sawai N, Kita M, Kodama T et al. Role of γ interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect. Immun.67, 279–285 (1999).
   PubMed Web of Science ®Google Scholar
• DeLyria ES, Redline RW, Blanchard TG. Vaccination of mice against H. pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology136, 247–256 (2009).
   PubMed Web of Science ®Google Scholar
• Velin D, Favre L, Bernasconi E et al. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology136, 2237–2246 (2009).
   PubMed Web of Science ®Google Scholar
• Garhart CA, Redline RW, Nedrud JG, Czinn SJ. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect. Immun.70, 3529–3538 (2002).
   PubMed Web of Science ®Google Scholar
• Lucas B, Bumann D, Walduck A et al. Adoptive transfer of CD4+ T cells specific for subunit A of Helicobacter pylori urease reduces H. pylori stomach colonization in mice in the absence of interleukin-4 (IL-4)/IL-13 receptor signaling. Infect. Immun.69, 1714–1721 (2001).
   PubMedGoogle Scholar
• Garhart CA, Nedrud JG, Heinzel FP, Sigmund NE, Czinn SJ. Vaccine-induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin-4. Infect. Immun.71, 3628–3633 (2003).
   PubMed Web of Science ®Google Scholar
• Garhart CA, Heinzel FP, Czinn SJ, Nedrud JG. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect. Immun.71, 910–921 (2003).
   PubMed Web of Science ®Google Scholar
• Panthel K, Faller G, Haas R. Colonization of C57BL/6J and BALB/c wild-type and knockout mice with Helicobacter pylori: effect of vaccination and implications for innate and acquired immunity. Infect. Immun.71, 794–800 (2003).
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity24, 179–189 (2006).
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB et al. Transforming growth factor-β induces development of the T(H)17 lineage. Nature441, 231–234 (2006).
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. J. Biol. Chem.278, 1910–1914 (2003).
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell126, 1121–1133 (2006).
   PubMed Web of Science ®Google Scholar
• Yang XO, Panopoulos AD, Nurieva R et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem.282, 9358–9363 (2007).
   PubMed Web of Science ®Google Scholar
• Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity21, 467–476 (2004).
   PubMed Web of Science ®Google Scholar
• Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med.194, 519–527 (2001).
   PubMed Web of Science ®Google Scholar
• Michetti M, Kelly CP, Kraehenbuhl JP, Bouzourene H, Michetti P. Gastric mucosal α(4)β(7)-integrin-positive CD4 T lymphocytes and immune protection against helicobacter infection in mice. Gastroenterology119, 109–118 (2000).
   PubMed Web of Science ®Google Scholar
• Velin D, Bachmann D, Bouzourene H, Michetti P. Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology129, 142–155 (2005).
   PubMed Web of Science ®Google Scholar
• Ismail HF, Fick P, Zhang J, Lynch RG, Berg DJ. Depletion of neutrophils in IL-10-/- mice delays clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter. J. Immunol.170, 3782–3789 (2003).
   PubMed Web of Science ®Google Scholar
• Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol.6, 329–333 (2006).
   PubMed Web of Science ®Google Scholar
• Rowland M, Kumar D, Daly L, O’Connor P, Vaughan D, Drumm B. Low rates of Helicobacter pylori reinfection in children. Gastroenterology117, 336–341 (1999).
   PubMedGoogle Scholar
• Strobel S. Immunity induced after a feed of antigen during early life: oral tolerance v. sensitisation. Proc. Nutr. Soc.60, 437–442 (2001).
   PubMed Web of Science ®Google Scholar
• Caruso R, Fina D, Paoluzi OA et al. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur. J. Immunol.38, 470–478 (2008).
   PubMed Web of Science ®Google Scholar
• Ernst PB, Gold BD. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu. Rev. Microbiol.54, 615–640 (2000).
   PubMed Web of Science ®Google Scholar
• Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med.345, 784–789 (2001).
   PubMed Web of Science ®Google Scholar
• Zucca E, Bertoni F, Roggero E et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N. Engl. J. Med.338, 804–810 (1998).
   PubMed Web of Science ®Google Scholar
• Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J. Infect Dis198, 553–560 (2008).
   PubMed Web of Science ®Google Scholar
• Gottwein JM, Blanchard TG, Targoni OS et al. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund’s adjuvant by systemic immunization. J. Infect. Dis.184, 308–314 (2001).
   PubMed Web of Science ®Google Scholar